Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model

Abstract Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexp...

Full description

Bibliographic Details
Main Authors: Tim Kaden, Katja Graf, Knut Rennert, Ruoya Li, Alexander S. Mosig, Martin Raasch
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-40004-z
_version_ 1797560041843195904
author Tim Kaden
Katja Graf
Knut Rennert
Ruoya Li
Alexander S. Mosig
Martin Raasch
author_facet Tim Kaden
Katja Graf
Knut Rennert
Ruoya Li
Alexander S. Mosig
Martin Raasch
author_sort Tim Kaden
collection DOAJ
description Abstract Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexpected side effects of severe hepatotoxicity, which was not detected by preclinical testing. To address the limitations of current drug testing strategies mainly involving 2D cell cultures and animal testing, a three-dimensional microphysiological model of the human liver containing expandable human liver sinusoidal endothelial cells, monocyte-derived macrophages and differentiated HepaRG cells was utilized to investigate the toxicity of trovafloxacin and compared it to the structurally-related non-toxic drug levofloxacin. In the model, trovafloxacin elicited vascular and hepatocellular toxicity associated with pro-inflammatory cytokine release already at clinically relevant concentrations, whereas levofloxacin did not provoke tissue injury. Similar to in vivo, cytokine secretion was dependent on a multicellular immune response, highlighting the potential of the complex microphysiological liver model for reliably detecting drug-related cytotoxicity in preclinical testing. Moreover, hepatic glutathione depletion and mitochondrial ROS formation were elucidated as intrinsic toxicity mechanisms contributing to trovafloxacin toxicity.
first_indexed 2024-03-10T17:53:47Z
format Article
id doaj.art-62d65595507140189e02dccd22b2bd5a
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-03-10T17:53:47Z
publishDate 2023-08-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-62d65595507140189e02dccd22b2bd5a2023-11-20T09:15:08ZengNature PortfolioScientific Reports2045-23222023-08-0113111810.1038/s41598-023-40004-zEvaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver modelTim Kaden0Katja Graf1Knut Rennert2Ruoya Li3Alexander S. Mosig4Martin Raasch5Dynamic42 GmbHDynamic42 GmbHDynamic42 GmbHBiopredic InternationalInstitute of Biochemistry II, Center for Sepsis Control and Care, Jena University HospitalDynamic42 GmbHAbstract Drug-induced liver injury induced by already approved substances is a major threat to human patients, potentially resulting in drug withdrawal and substantial loss of financial resources in the pharmaceutical industry. Trovafloxacin, a broad-spectrum fluoroquinolone, was found to have unexpected side effects of severe hepatotoxicity, which was not detected by preclinical testing. To address the limitations of current drug testing strategies mainly involving 2D cell cultures and animal testing, a three-dimensional microphysiological model of the human liver containing expandable human liver sinusoidal endothelial cells, monocyte-derived macrophages and differentiated HepaRG cells was utilized to investigate the toxicity of trovafloxacin and compared it to the structurally-related non-toxic drug levofloxacin. In the model, trovafloxacin elicited vascular and hepatocellular toxicity associated with pro-inflammatory cytokine release already at clinically relevant concentrations, whereas levofloxacin did not provoke tissue injury. Similar to in vivo, cytokine secretion was dependent on a multicellular immune response, highlighting the potential of the complex microphysiological liver model for reliably detecting drug-related cytotoxicity in preclinical testing. Moreover, hepatic glutathione depletion and mitochondrial ROS formation were elucidated as intrinsic toxicity mechanisms contributing to trovafloxacin toxicity.https://doi.org/10.1038/s41598-023-40004-z
spellingShingle Tim Kaden
Katja Graf
Knut Rennert
Ruoya Li
Alexander S. Mosig
Martin Raasch
Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
Scientific Reports
title Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
title_full Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
title_fullStr Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
title_full_unstemmed Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
title_short Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
title_sort evaluation of drug induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model
url https://doi.org/10.1038/s41598-023-40004-z
work_keys_str_mv AT timkaden evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel
AT katjagraf evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel
AT knutrennert evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel
AT ruoyali evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel
AT alexandersmosig evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel
AT martinraasch evaluationofdruginducedlivertoxicityoftrovafloxacinandlevofloxacininahumanmicrophysiologicallivermodel